Corbus Pharmaceuticals (CRBP) Stock: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$8.12
-0.12 (-1.46%)
▼
5d:
-29.14%
30d:
-16.8%
90d:
+4.37%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CRBP is down 29.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CRBP is down 29.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $8.12, which is considered oversold relative to its 30-day fair value range of $9.25 to $11.08.
Technical Outlook: Technically, CRBP is showing sideways momentum. The price is currently testing key support at $7.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $34.02 (+319.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRBP is showing sideways momentum. The price is currently testing key support at $7.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $34.02 (+319.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.25 -
$11.08
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 319.0% below Wall St target ($34.02)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.25 -
$11.08
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.95
Resistance Level
$11.60
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.47
Wall Street Target
$34.03
(+319.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 13, 2026 3:59 PM ET
Data refreshes hourly during market hours. Next update: 4:59 PM
Data refreshes hourly during market hours. Next update: 4:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$106 | 41 HOLD |
